HAE · NYSE · STOCK
Haemonetics (HAE) Stock Analysis
$90.19
52W $47.32 – $92.25
53/100
$4.13B
44.1
0.52
Is HAE Bullish or Bearish?
Mixed.
Innellis AI committee rates Haemonetics (HAE) Watch with a composite score of 53/100
, based on 6 analysts with 33% agreement.
Last updated August 17, 2026.
What Would Change This View
- Upgrade to Buy
- Requires a committee score of 60.0 — +7.46 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Reduce
- Requires the score to fall below 40.0 — -12.54 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 1.54) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull & Bear Case
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- News sentiment is positive (+0.20 across 19 articles, 14d) — News
Bear Case
- P/E of 43.2 is expensive by classic value standards — Value
- Debt-to-equity of 1.54 adds balance-sheet risk to the value case — Value
- EPS declining -37.4% YoY despite any revenue growth — Growth
- Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
- RSI at 73 is in overbought territory — Technical
- Weekly RSI at 83 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 17, 2026
Overall Committee Score
53/100
Agreement
33%
Analysts
6
Conviction
Contested
Sector Rank
Top 96%
of 192 Healthcare peers
Value Analyst
bearish
37
/ 100 · Moderate confidence
Multiples don't clear a genuine value bar here, or cheapness looks justified by weak fundamentals
− P/E of 43.2 is expensive by classic value standards
Growth Analyst
neutral
44
/ 100 · High confidence
Moderate growth -- present but not remarkable
+ 5 consecutive earnings beats -- consistent execution
− EPS declining -37.4% YoY despite any revenue growth
Technical Analyst
neutral
58
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 73 is in overbought territory
Risk Analyst
bearish
32
/ 100 · Moderate confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− High leverage (debt-to-equity 1.54) amplifies downside in a stress scenario
Macro Analyst
bullish
80
/ 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
bullish
64
/ 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.20 across 19 articles, 14d)
Portfolio Manager
neutral
45
/ 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2963.04)
Investment Thesis Evolution
Committee score moved marginally from 52.5 to 52.5.
- New bearish signals: 1 appeared.
- Bearish pressure eased: 1 signal(s) disappeared.
Analyst-level changes:
- Portfolio Manager: +1 bearish signal(s).
Comparing 2026-08-16 to 2026-08-17 (1 day apart).
Technical Analysis
RSI (14)
72.8
Overbought
MACD Histogram
0.406
Bullish Momentum
Trend Direction
Uptrend
Weekly: Sideways
Market Structure
Hh Hl
Support
$84.46
Resistance
$91.29
Bollinger %B
0.87
Inside Bands
Price vs Moving Averages
EMA 9
$88.07
Above
EMA 21
$84.64
Above
EMA 50
$78.89
Above
EMA 200
$70.06
Above
Fundamental Analysis
Valuation
49
Growth
56
Profitability
58
Financial Health
77
Cash Flow
70
Valuation
P/E Ratio
44.1×
P/B Ratio
4.92×
PEG Ratio
-1.18
Dividend Yield
0.00%
52W High
$92.25
52W Low
$47.32
Quality & Growth
ROE
1222.0%
ROA
406.1%
Gross Margin
5738.4%
Operating Margin
1817.6%
Revenue Growth YoY
—
Debt / Equity
1.40
AI Fundamental Assessment
P/E ratio of 44.1 (rich relative to a 15-40x range); Price-to-book of 4.9x; PEG ratio of -1.2 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 12.2%; Return on assets of 4.1%; Net margin of 7.1%; Gross margin of 57.4%; Current ratio of 3.08 (healthy short-term liquidity); Debt-to-equity of 1.40; Free cash flow per share is positive (6.42); Most recent quarter beat estimates by 4.8%; 5 consecutive earnings beats; EPS growth decelerating (-1.5% -> -11.6% QoQ); Average YoY EPS growth of 3.6%; Analyst estimates falling over recent quarters
Get the Full HAE Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →